Search alternatives:
greater decrease » greatest decrease (Expand Search), greater increase (Expand Search), greater disease (Expand Search)
we decrease » _ decrease (Expand Search), mean decrease (Expand Search), teer decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
greater decrease » greatest decrease (Expand Search), greater increase (Expand Search), greater disease (Expand Search)
we decrease » _ decrease (Expand Search), mean decrease (Expand Search), teer decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
17801
Revisiting the association between sodium-glucose cotransporter-2 inhibitors and the risk of neoplasm in patients with type 2 diabetes: new insights from an updated systematic revi...
Published 2025“…</p> <p>Type 2 diabetes (T2D) is a chronic metabolic disease that affects 1 in 10 people worldwide, and cancer is now recognized as a common and severe complication of T2D. …”
-
17802
USUV replicates in STAT1-sufficient peripheral tissues leading to spleen and liver pathology.
Published 2025“…<b>(G)</b> H&E staining of spleen tissue collected from mock or USUV-infected mice with a 200 µm scale bar. Decreased red pulp due to massive immune cell infiltration was observed in Vav-Cre/<i>Stat1</i><sup>fl/fl</sup> and <i>Stat1</i><sup>-/-</sup> mice. …”
-
17803
CDCP1 regulates CDA and hENT1 expression through c-Src/PKCδ signaling pathway.
Published 2025“…<p>(A, B) Quantitative PCR analysis of CDA and hENT1 mRNA expression levels in T24, T24-CD, and T24-CDKO cells. …”
-
17804
Table 9_Exploring Histoplasma species seroprevalence and risk factors for seropositivity in The Gambia’s working equid population: Baseline analysis of the Tackling Histoplasmosis...
Published 2024“…The primary aims of this study were to estimate anti-Histoplasma antibody seroprevalence in the equid population in rural The Gambia and to explore risk factors for seropositivity.</p>Methods<p>A nationwide cross-sectional study was conducted (February–July 2022), representing baseline measurements of a longitudinal cohort study. …”
-
17805
Table 1_Exploring Histoplasma species seroprevalence and risk factors for seropositivity in The Gambia’s working equid population: Baseline analysis of the Tackling Histoplasmosis...
Published 2024“…The primary aims of this study were to estimate anti-Histoplasma antibody seroprevalence in the equid population in rural The Gambia and to explore risk factors for seropositivity.</p>Methods<p>A nationwide cross-sectional study was conducted (February–July 2022), representing baseline measurements of a longitudinal cohort study. …”
-
17806
Table 2_Exploring Histoplasma species seroprevalence and risk factors for seropositivity in The Gambia’s working equid population: Baseline analysis of the Tackling Histoplasmosis...
Published 2024“…The primary aims of this study were to estimate anti-Histoplasma antibody seroprevalence in the equid population in rural The Gambia and to explore risk factors for seropositivity.</p>Methods<p>A nationwide cross-sectional study was conducted (February–July 2022), representing baseline measurements of a longitudinal cohort study. …”
-
17807
Table 10_Exploring Histoplasma species seroprevalence and risk factors for seropositivity in The Gambia’s working equid population: Baseline analysis of the Tackling Histoplasmosis...
Published 2024“…The primary aims of this study were to estimate anti-Histoplasma antibody seroprevalence in the equid population in rural The Gambia and to explore risk factors for seropositivity.</p>Methods<p>A nationwide cross-sectional study was conducted (February–July 2022), representing baseline measurements of a longitudinal cohort study. …”
-
17808
Table 3_Exploring Histoplasma species seroprevalence and risk factors for seropositivity in The Gambia’s working equid population: Baseline analysis of the Tackling Histoplasmosis...
Published 2024“…The primary aims of this study were to estimate anti-Histoplasma antibody seroprevalence in the equid population in rural The Gambia and to explore risk factors for seropositivity.</p>Methods<p>A nationwide cross-sectional study was conducted (February–July 2022), representing baseline measurements of a longitudinal cohort study. …”
-
17809
Table 8_Exploring Histoplasma species seroprevalence and risk factors for seropositivity in The Gambia’s working equid population: Baseline analysis of the Tackling Histoplasmosis...
Published 2024“…The primary aims of this study were to estimate anti-Histoplasma antibody seroprevalence in the equid population in rural The Gambia and to explore risk factors for seropositivity.</p>Methods<p>A nationwide cross-sectional study was conducted (February–July 2022), representing baseline measurements of a longitudinal cohort study. …”
-
17810
Table 6_Exploring Histoplasma species seroprevalence and risk factors for seropositivity in The Gambia’s working equid population: Baseline analysis of the Tackling Histoplasmosis...
Published 2024“…The primary aims of this study were to estimate anti-Histoplasma antibody seroprevalence in the equid population in rural The Gambia and to explore risk factors for seropositivity.</p>Methods<p>A nationwide cross-sectional study was conducted (February–July 2022), representing baseline measurements of a longitudinal cohort study. …”
-
17811
Table 5_Exploring Histoplasma species seroprevalence and risk factors for seropositivity in The Gambia’s working equid population: Baseline analysis of the Tackling Histoplasmosis...
Published 2024“…The primary aims of this study were to estimate anti-Histoplasma antibody seroprevalence in the equid population in rural The Gambia and to explore risk factors for seropositivity.</p>Methods<p>A nationwide cross-sectional study was conducted (February–July 2022), representing baseline measurements of a longitudinal cohort study. …”
-
17812
Table 4_Exploring Histoplasma species seroprevalence and risk factors for seropositivity in The Gambia’s working equid population: Baseline analysis of the Tackling Histoplasmosis...
Published 2024“…The primary aims of this study were to estimate anti-Histoplasma antibody seroprevalence in the equid population in rural The Gambia and to explore risk factors for seropositivity.</p>Methods<p>A nationwide cross-sectional study was conducted (February–July 2022), representing baseline measurements of a longitudinal cohort study. …”
-
17813
Table 7_Exploring Histoplasma species seroprevalence and risk factors for seropositivity in The Gambia’s working equid population: Baseline analysis of the Tackling Histoplasmosis...
Published 2024“…The primary aims of this study were to estimate anti-Histoplasma antibody seroprevalence in the equid population in rural The Gambia and to explore risk factors for seropositivity.</p>Methods<p>A nationwide cross-sectional study was conducted (February–July 2022), representing baseline measurements of a longitudinal cohort study. …”
-
17814
Supplementary file 1_Structural and functional disconnections in non-acute post-stroke patients.docx
Published 2025“…</p>Results<p>Compared with HCs, significant decreases in both SC and FC were observed in stroke patients among the right precentral gyrus, right superior frontal gyrus, right supplementary motor area, right paracentral lobule, right middle cingulate gyrus, right superior marginal gyrus, right middle temporal gyrus, and left inferior temporal gyrus. …”
-
17815
Table 4_Analysis of global trends in acute lymphoblastic leukemia in children aged 0–5 years from 1990 to 2021.docx
Published 2025“…Background<p>Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer, with a significant global burden. This study evaluates global, regional, and national trends in the prevalence, mortality, and disability-adjusted life years (DALYs) of childhood ALL from 1990 to 2021, providing insights into disparities and progress across different socio-demographic and geographic contexts.…”
-
17816
Image 1_Analysis of global trends in acute lymphoblastic leukemia in children aged 0–5 years from 1990 to 2021.tif
Published 2025“…Background<p>Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer, with a significant global burden. This study evaluates global, regional, and national trends in the prevalence, mortality, and disability-adjusted life years (DALYs) of childhood ALL from 1990 to 2021, providing insights into disparities and progress across different socio-demographic and geographic contexts.…”
-
17817
Table 2_Analysis of global trends in acute lymphoblastic leukemia in children aged 0–5 years from 1990 to 2021.docx
Published 2025“…Background<p>Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer, with a significant global burden. This study evaluates global, regional, and national trends in the prevalence, mortality, and disability-adjusted life years (DALYs) of childhood ALL from 1990 to 2021, providing insights into disparities and progress across different socio-demographic and geographic contexts.…”
-
17818
Table 1_Analysis of global trends in acute lymphoblastic leukemia in children aged 0–5 years from 1990 to 2021.docx
Published 2025“…Background<p>Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer, with a significant global burden. This study evaluates global, regional, and national trends in the prevalence, mortality, and disability-adjusted life years (DALYs) of childhood ALL from 1990 to 2021, providing insights into disparities and progress across different socio-demographic and geographic contexts.…”
-
17819
Table 3_Analysis of global trends in acute lymphoblastic leukemia in children aged 0–5 years from 1990 to 2021.docx
Published 2025“…Background<p>Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer, with a significant global burden. This study evaluates global, regional, and national trends in the prevalence, mortality, and disability-adjusted life years (DALYs) of childhood ALL from 1990 to 2021, providing insights into disparities and progress across different socio-demographic and geographic contexts.…”
-
17820
Figure 2 from Targeting PRMT1 Reduces Cancer Persistence and Tumor Relapse in <i>EGFR</i>- and <i>KRAS</i>-Mutant Lung Cancer
Published 2025“…<b>A</b> and <b>B,</b> Cells were treated with type I PRMT inhibitors (PRMTi) at 0.1 or 1 μmol/L, with (<b>A</b>) or without (<b>B</b>) targeted drugs. …”